Jakavi 5 mg/ml, Lösung zum Einnehmen

7680697220016 CH-69722 L01EJ01 07.16.1.
Jakavi 5 mg/ml, Lösung zum Einnehmen
Jakavi 5 mg/ml, Lösung zum Einnehmen
Jakavi 5 mg/ml, Lösung zum Einnehmen
1 / 3
google

Details

Product number
6972201
CPT
-
Packaging group
60
Unit
ml
Composition
ruxolitinibum 5 mg ut ruxolitinibi phosphas, propylenglycolum 150.0 mg, E 218 1.2 mg, propylis parahydroxybenzoas 0.4 mg, sucralosum, acidum citricum, aromatica (Erdbeer), aqua purificata, ad solutionem pro 1 ml.

Articles (1)

Jakavi 5 mg/ml, Lösung zum Einnehmen
Lösung
60
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
(N/A)
5.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
150.0 MG Substance HBESI
(N/A)
1.2 MG Substance HBESI
(N/A)
0.4 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance AROMA
(N/A)
- Substance HNIDK

Authorization holder

Novartis Pharma Schweiz AG

6343 Risch

Authorization information

Swissmedic authorization number
69722
Drug name
Jakavi, Lösung zum Einnehmen
Galenic form
LSOR
ATC Code
L01EJ01
Authorization status
Z
Dispensation category
A
First authorization
27/03/2025
Authorization expiration date
26/03/2030
IT number
07.16.1.
Domain
Human medicine
Field of application
akute Graft-versus-Host-Krankheit

Packaging details

Description (FR)
JAKAVI 5 mg/ml sol 5 mg 60 ml
Description (DE)
JAKAVI 5 mg/ml Lös 5 mg 60 ml
Market launch
15/06/2025
Narcotic (BTM)
No